Waycross Investment Management Co Takes $1.11 Million Position in Medtronic PLC $MDT

Posted by Brenda Bartman on Sep 3rd, 2026

Waycross Investment Management Co purchased a new position in Medtronic PLC (NYSE:MDT – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,179 shares of the medical technology company’s stock, valued at approximately $1,109,000. Medtronic comprises about 0.6% of Waycross Investment Management Co’s investment portfolio, making the stock its 29th largest position.

Other institutional investors have also added to or reduced their stakes in the company. Tranquilli Financial Advisor LLC boosted its holdings in Medtronic by 37.6% during the 2nd quarter. Tranquilli Financial Advisor LLC now owns 9,712 shares of the medical technology company’s stock valued at $760,000 after acquiring an additional 2,655 shares during the period. Coppell Advisory Solutions LLC purchased a new position in Medtronic in the 2nd quarter worth approximately $251,000. Sound Financial Strategies Group LLC increased its stake in Medtronic by 4.7% in the 2nd quarter. Sound Financial Strategies Group LLC now owns 3,029 shares of the medical technology company’s stock worth $237,000 after purchasing an additional 136 shares during the period. Symphony Financial Ltd. Co. lifted its position in Medtronic by 31.8% in the second quarter. Symphony Financial Ltd. Co. now owns 3,893 shares of the medical technology company’s stock valued at $312,000 after purchasing an additional 939 shares during the last quarter. Finally, Banco de Sabadell S.A lifted its position in Medtronic by 1.4% in the second quarter. Banco de Sabadell S.A now owns 21,155 shares of the medical technology company’s stock valued at $1,656,000 after purchasing an additional 290 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Monday, August 10th. Stifel Nicolaus boosted their price objective on shares of Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a research report on Wednesday. Needham & Company LLC upped their price objective on shares of Medtronic from $101.00 to $114.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Wells Fargo & Company increased their target price on shares of Medtronic from $102.00 to $104.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $88.00 target price on shares of Medtronic in a research note on Thursday, June 4th. Nineteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Medtronic currently has an average rating of “Moderate Buy” and a consensus target price of $102.96.

Read Our Latest Report on Medtronic

Medtronic Stock Performance

Shares of MDT stock opened at $92.10 on Thursday. The firm has a market capitalization of $117.89 billion, a price-to-earnings ratio of 22.69, a PEG ratio of 2.15 and a beta of 0.56. The stock has a fifty day moving average of $86.27 and a 200 day moving average of $85.35. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52.

Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.89%. The business had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. During the same period in the previous year, the firm earned $1.26 EPS. The company’s quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, research analysts expect that Medtronic PLC will post 5.96 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s payout ratio is currently 70.94%.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Broad earnings beat and stronger outlook: Medtronic reported adjusted EPS of $1.45, above the $1.39 consensus, while revenue increased 13.7% year over year to $9.76 billion, exceeding estimates of $9.55 billion. Management raised fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00. Medtronic fiscal 2027 results
Positive Sentiment: Growth was broad-based: Cardiovascular revenue rose 19.5%, neuroscience increased 10.3%, medical surgical grew 10.0% and diabetes advanced 16.9%. Analysts characterized the results as evidence of a potential growth acceleration across both established franchises and newer platforms. Medtronic beat-and-raise analysis
Positive Sentiment: Robotics and heart-tech expansion: Medtronic committed approximately $700 million to a strategic partnership with Cornerstone Robotics, gaining distribution rights for its Sentire surgical system in select markets outside the United States. It also agreed to invest up to $80 million in Pi-Cardia to support complex TAVR procedures. These moves could broaden Medtronic’s long-term growth opportunities in minimally invasive surgery and structural heart care. Cornerstone Robotics partnership
Positive Sentiment: Analyst support increased: RBC reaffirmed an Outperform rating and set a $118 price target. BTIG raised its target to $100 and maintained a Buy rating, while Baird lifted its target to $100. These revisions indicate improving confidence in Medtronic’s earnings trajectory. Analyst price-target revisions
Neutral Sentiment: Some caution remains: Stifel raised its price target to $95 but kept a Hold rating, and Baird retained a Neutral rating despite its higher target. The second-quarter EPS outlook of $1.32-$1.34 is below the $1.35 consensus, suggesting investors may continue to watch execution and the sustainability of the recent growth acceleration.

Insider Activity

In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.27% of the stock is owned by corporate insiders.

Medtronic Company Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).